SPRY R&D Expense Growth
Ars Pharmaceuticals Inc · R&D Expense Growth
SPRY R&D Expense Growth
Latest reported8.35%period ending
SPRY Quarterly R&D Growth (QoQ) (0.00% → 8.35%)
Latest values, visible window
High-resolution chart · PNG
SPRY r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 8.3487% | |
| 25.9367% | |
| 25.1545% | |
| -31.8216% | |
| 36.687% | |
| -2.4777% | |
| -31.5623% | |
| -35.8614% | |
| 31.7539% | |
| 53.7603% | |
| 13.3911% | |
| -58.9217% | |
| 11.5385% | |
| 39.1083% | |
| 20.9864% | |
| -10.5057% | |
| -19.7861% | |
| 38.5539% | |
| -23.5845% | |
| -8.8369% | |
| 0% | |
| -35.0312% | |
| 0% | |
| 16.6784% | |
| -31.8508% | |
| 0% |